Flu vaccine without the eggs approved


Flublok from US biotech Protein Sciences has become the first flu vaccine made using an insect virus to win marketing approval in the US.

Historically, manufacturers have produced vaccine by growing the virus in eggs and then modifying it. This is effective but requires millions of fertilised eggs each year. This also means the vaccine can be unsuitable for people with egg allergies.

Growing the virus in cell lines is an alternative and, unlike eggs, cells can be frozen for later use, raising the possibility of responding to emergencies more rapidly.

In November 2012, the FDA approved Flucelvax from Novartis: the first vaccine based on cell lines, rather than eggs, to reach the market. Flublok is different in that its manufacture does not require flu viruses. It contains three, full-length, recombinant haemagglutinin proteins to help protect against two influenza virus A strains, H1N1 and H3N2, and one influenza virus B strain.


Related Content

Fighting the flu

31 January 2011 Premium contentFeature

news image

The threat of pandemic influenza is constantly on the horizon. Clare Sansom explores the latest attempts to tackle an ever-ch...

Pharma's year of merger mania

15 December 2009 News Archive

news image

Our round-up of the pharmaceutical industry in 2009 shows the fallout from this year's mega-mergers has swept across the sect...

Most Commented

How to print a crystal in 3D

17 April 2014 Research

news image

Rather than looking at a crystal on a screen, print it out and hold it in your hand

The sultan of synthesis

11 April 2014 Feature

news image

Phil Baran is spurring organic chemists to rethink how they make complex compounds, as Mark Peplow discovers